Europe Viral Vector And Plasmid DNA Manufacturing Market Size | Companies
The europe viral vector and plasmid DNA manufacturing market size was USD 1.85 billion in 2023, calculated at USD 2.22 billion in 2024 and is expected to reach around USD 11.65 billion by 2033, expanding at a CAGR of 20.2% from 2024 to 2033.
The growth of the viral vector and plasmid DNA manufacturing market in Europe is primarily driven by increased research funding and the strong presence of local key market players. The biopharmaceutical industry in Europe is experiencing significant expansion, largely due to growing investments in this sector. For example, in February 2022, the UK government committed approximately USD 192 million to the Coalition for Epidemic Preparedness Innovations (CEPI) to enhance vaccine development efforts. This investment is a clear indicator of the region’s dedication to advancing biotechnology and pharmaceutical research.
In 2023, the European viral vector and plasmid DNA manufacturing market captured a 24.8% share of the global industry. One of the key factors contributing to this growth is the rapidly aging population in Europe. According to the United Nations, individuals aged 65 and older constitute 19% of the European population, equating to around 183 million people. This demographic is particularly vulnerable to infectious diseases, such as the flu, which often require hospitalization. As a result, the demand for advanced medical treatments, including vaccines and gene therapies, is expected to rise, driving further growth in the market.
The region's market growth is also supported by the presence of several companies specializing in vaccine production, which in turn, is boosting the manufacturing of viral vectors in European countries. For instance, Exothera S.A., a Contract Development and Manufacturing Organization (CDMO) based in Belgium, has made substantial investments in expanding its viral vector technologies. In March 2022, Exothera S.A. partnered with IDT Biologika to establish a manufacturing facility focused on viral vector-based vaccines, highlighting the strategic importance of these technologies in the fight against infectious diseases.
Furthermore, in October 2022, ABL and RD-Biotech entered into a partnership aimed at advancing cell and gene therapy manufacturing. This collaboration brings together ABL’s expertise in Good Manufacturing Practice (GMP) for viral vectors and RD-Biotech’s proficiency in GMP for plasmid DNA. This partnership is expected to accelerate the development of innovative therapies, ultimately reducing the time it takes for these treatments to reach the market.
In summary, Europe’s viral vector and plasmid DNA manufacturing market is poised for significant growth due to a combination of increased research funding, strategic partnerships, and the region’s focus on addressing the healthcare needs of an aging population. These factors are expected to create substantial opportunities for market expansion in the coming years.
| Report Attribute | Details |
| Market Size in 2025 | USD 2.67 Billion |
| Market Size by 2033 | USD 11.65 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 20.2% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Vector type, workflow, application, end-use, disease |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Merck KGaA; Lonza; BioMarin; Batavia Biosciences; BioNTech IMFS; Miltenyi Biotec; Charles River Laboratories (Cobra Biologics); FUJIFILM Holdings Corporation; Thermo Fisher Scientific, Inc. |
Based on vector type, the adenovirus segment held a considerable share in 2023. Adenoviral Vectors (AdV) are increasingly used for various research applications in gene therapy as they can be produced at high titers and integrate large transgenes and transduce quiescent & dividing cells. For instance, scientists are engaged in R&D of adenovirus-mediated gene therapy to cure HIV infection. This adenoviral gene therapy could be an effective way to improve HIV management. AdV are extensively employed as vaccines as they can induce strong humoral and T cell responses. Several studies have been carried out to evaluate the efficiency of AdV across various applications such as vaccinology and gene editing. Studies based on AdV as a delivery tool for CRISPR/Cas9 have resulted in effective gene disruption in the host genome of various human cells.
The lentivirus segment is projected to grow at the fastest CAGR of 20.3% during the forecast period. With the increasing use of lentiviral vectors in ongoing research, the research community is focusing on advancements in these vectors. For instance, scientists are studying the potential of non-integrating lentiviral vectors (NILVs) as a tool to avoid insertional mutagenesis. NILVs can transduce both non-dividing and dividing cells. These vectors have potential applications in CAR-T cell therapy research. Furthermore, a recent study published in June 2022 stated that lentiviral vectors are being used to develop vaccines targeting dendritic cells and stimulating a powerful T-cell immune response. The same study stated that lentivirus vectors are being used to produce vaccines against SARS-CoV-2. It also offers protection and treatment against HIV. Numerous applications of this vector have contributed to segment growth
Based on workflow, the downstream processing segment dominated the market with the largest revenue share of 53.15% in 2023. Downstream processes involve several purification methods that consist of multiple steps. These processes are typically divided into three stages: capture, intermediate purification, and polishing. For intermediate purification and the final polishing step, chromatography and ultrafiltration techniques are utilized. In the industry, chromatography techniques using ion exchange and affinity methods are the most preferred. However, these methods have certain challenges. For instance, they require additional purification methods, resulting in a loss of yield.
The upstream processing segment is expected to grow at a CAGR of 19.2% over the forecast period.The first stage of processing, known as upstream processing, involves introducing cells to the virus, growing these cells, and then extracting the virus from them. Increasing innovation in product development, such as the ambr 15 microbioreactor system for high throughput upstream process development, is expected to enhance this specific area.
Based on the application, the vaccinology segment dominated the market with the largest revenue share of 21.19% in 2023. The growing demand for vaccines to cure infectious diseases such as Coronavirus and cancer is projected to boost market growth. Manufacturing of viral vector-based vaccines is easy and can be accomplished along with manufacturing of other traditional vaccines in large manufacturing units. The safety profiles of these vaccines can also be easily determined. Several viral vectors are being investigated owing to their associated advantages, which are being explored to assess their potential and accelerate the development of viral vector-based vaccines.
The cell therapy segment is expected to grow at a CAGR of 22.2% over the forecast period. Cell therapy-based treatments are becoming more popular due to the development of advanced transfer vectors. These vectors are safe and effective. In this process, patient samples are expanded, extracted, and then modified using gene therapy vectors. The modified cells are subsequently re-implanted into patients for therapeutic purposes.
Based on end-use, the research institutes segment dominated the market with the largest revenue share of 57.18% in 2023. The segment growth is attributed to the increase in the demand for viral vectors and the increasing involvement of scientific communities in gene and cell therapy research. Research activities carried out for improvement in vector production by research entities are driving the segment.
The pharmaceutical and biotechnology companies’ segment is expected to grow at a CAGR of 20.6% over the forecast period. This can be attributed to continuous introduction of advanced therapies coupled with subsequent increase in the number of gene therapy-based research programs by pharmaceutical firms. The number of biotech companies that are employing vectors for therapeutic production continues to increase over time.
Based on disease, the cancer segment dominated the market with the largest revenue share of 38.19% in 2023. An increasing number of cancer cases and a high number of plasmid DNA and viral vectors for the development of these gene therapies are anticipated to drive the segment’s growth. Furthermore, the adoption of a Western lifestyle, poor diet, and lack of physical activities are responsible for an increase in cancer cases.
The genetic disorders are expected to grow rapidly during the forecast period. Gene therapy was developed for the treatment of rare genetic disorders like hemophilia, Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID), and Lipoprotein Lipase Deficiency (LPLD) diseases, which are caused due to genetic inconsistencies or missing genes that express a particular trait. Genetic diseases are most commonly congenital; however, some diseases can be acquired by random mutations. The most common genetic diseases include sickle cell anemia and hemophilia, which are characterized by formation of blood clots and production of hemoglobin, affecting the oxygen-carrying capacity of the blood.
Germany viral vector and plasmid DNA manufacturing market accounted for a revenue share of 24.19% in 2023. Germany is one of the leading gene therapy clinical trials countries in Europe. A substantial number of companies have their facilities set up here, which is anticipated to support the rapid commercialization of drugs. Germany is the first country where the recently approved gene therapy treatment has been utilized. It is expected to witness significant growth in the number of trials and approval of drugs in the coming years, owing to an increase in the number of companies being set up and the support provided by governments in finding feasible treatment options for genetic disorders & various cancers.
The viral vector and plasmid DNA manufacturing market in Italy is expected to grow at a CAGR of 19.4% over the forecast period due to tremendous advances in biomanufacturing and industrial research. The country hosts several biotechnology & biopharmaceutical hotspots and is home to several key players in the viral vectors and plasmid DNA manufacturing domain. For instance, Milan is the hub of the biotechnology sector in Italy, housing approximately 35% of all biotech companies.
Merck KGaA, Lonza, and BioMarin are among the key players operating in the market.
Merck KGaA provides a wide range of pharmaceutical and chemical products catering to various industries. It operates through three business sectors: healthcare, life sciences, and performance materials. It offers life sciences products and services for drug discovery & development, along with research & laboratory applications.
Lonza is a worldwide supplier of biopharmaceuticals and offers products in bioresearch, consumer care, agro-ingredients, pharmaceutical & biotechnology, water treatment, industrial solutions, and wood protection.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe Viral Vector And Plasmid DNA Manufacturing market.
By Vector Type
By Workflow
By Application
By End-use
By Disease
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vector type
1.2.2. Workflow
1.2.3. Application
1.2.4. End-use
1.2.5. Disease
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
3.2.1.2. Technological Advancements in Manufacturing Vectors
3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
3.2.2. Market restraint analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis
4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
4.2. Adeno-associated virus (AAV)
4.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.3. Lentivirus
4.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.4. Adenovirus
4.4.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.5. Retrovirus
4.5.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.6. Plasmids
4.6.1. Market estimates and forecasts 2021 to 2033, (USD Million)
4.7. Others
4.7.1. Market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis
5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
5.2. Upstream Manufacturing
5.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
5.2.2. Vector Amplification & Expansion
5.2.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
5.2.3. Vector Recovery/Harvesting
5.2.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
5.3. Downstream Manufacturing
5.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
5.3.2. Purification
5.3.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
5.3.3. Fill Finish diagnostic instruments
5.3.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis
6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
6.2. Gene Therapy
6.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
6.3. Cell Therapy
6.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
6.4. Vaccinology
6.4.1. Market estimates and forecasts 2021 to 2033, (USD Million)
6.5. Research Applications
6.5.1. Market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis
7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
7.2. Pharmaceutical and Biopharmaceutical Companies
7.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
7.3. Research Institutes
7.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis
8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
8.2. Cancer
8.2.1. Market estimates and forecasts 2021 to 2033, (USD Million)
8.3. Genetic Disorders
8.3.1. Market estimates and forecasts 2021 to 2033, (USD Million)
8.4. Infectious Diseases
8.4.1. Market estimates and forecasts 2021 to 2033, (USD Million)
8.5. Other
8.5.1. Market estimates and forecasts 2021 to 2033, (USD Million)
Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2023 & 2030
9.2. North America
9.2.1. North America market estimates and forecasts 2021 to 2033, (USD Million)
9.2.2. U.S.
9.2.2.1. Key country dynamics
9.2.2.2. Regulatory framework
9.2.2.3. Competitive scenario
9.2.2.4. U.S. market estimates and forecasts 2021 to 2033, (USD Million)
9.2.2.5. Target disease prevalence
9.2.3. Canada
9.2.3.1. Key country dynamics
9.2.3.2. Regulatory framework
9.2.3.3. Competitive scenario
9.2.3.4. Canada market estimates and forecasts 2021 to 2033, (USD Million)
9.2.3.5. Target disease prevalence
9.3. Europe
9.3.1. Europe market estimates and forecasts 2021 to 2033, (USD Million)
9.3.2. UK
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. UK market estimates and forecasts 2021 to 2033, (USD Million)
9.3.2.5. Target disease prevalence
9.3.3. Germany
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Germany market estimates and forecasts 2021 to 2033, (USD Million)
9.3.3.5. Target disease prevalence
9.3.4. France
9.3.4.1. Key country dynamics
9.3.4.2. Regulatory framework
9.3.4.3. Competitive scenario
9.3.4.4. France market estimates and forecasts 2021 to 2033, (USD Million)
9.3.4.5. Target disease prevalence
9.3.5. Italy
9.3.5.1. Key country dynamics
9.3.5.2. Regulatory framework
9.3.5.3. Competitive scenario
9.3.5.4. Italy market estimates and forecasts 2021 to 2033, (USD Million)
9.3.5.5. Target disease prevalence
9.3.6. Spain
9.3.6.1. Key country dynamics
9.3.6.2. Regulatory framework
9.3.6.3. Competitive scenario
9.3.6.4. Spain market estimates and forecasts 2021 to 2033, (USD Million)
9.3.6.5. Target disease prevalence
9.3.7. Norway
9.3.7.1. Key country dynamics
9.3.7.2. Regulatory framework
9.3.7.3. Competitive scenario
9.3.7.4. Norway market estimates and forecasts 2021 to 2033, (USD Million)
9.3.7.5. Target disease prevalence
9.3.8. Sweden
9.3.8.1. Key country dynamics
9.3.8.2. Regulatory framework
9.3.8.3. Competitive scenario
9.3.8.4. Sweden market estimates and forecasts 2021 to 2033, (USD Million)
9.3.8.5. Target disease prevalence
9.3.9. Denmark
9.3.9.1. Key country dynamics
9.3.9.2. Regulatory framework
9.3.9.3. Competitive scenario
9.3.9.4. Denmark market estimates and forecasts 2021 to 2033, (USD Million)
9.3.9.5. Target disease prevalence
9.4. Asia Pacific
9.4.1. Asia Pacific market estimates and forecasts 2021 to 2033, (USD Million)
9.4.2. Japan
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Japan market estimates and forecasts 2021 to 2033, (USD Million)
9.4.2.5. Target disease prevalence
9.4.3. China
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. China market estimates and forecasts 2021 to 2033, (USD Million)
9.4.3.5. Target disease prevalence
9.4.4. India
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. India market estimates and forecasts 2021 to 2033, (USD Million)
9.4.4.5. Target disease prevalence
9.4.5. Australia
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Australia market estimates and forecasts 2021 to 2033, (USD Million)
9.4.5.5. Target disease prevalence
9.4.6. South Korea
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. South Korea market estimates and forecasts 2021 to 2033, (USD Million)
9.4.6.5. Target disease prevalence
9.4.7. Thailand
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Thailand market estimates and forecasts 2021 to 2033, (USD Million)
9.4.7.5. Target disease prevalence
9.5. Latin America
9.5.1. Latin America market estimates and forecasts 2021 to 2033, (USD Million)
9.5.2. Brazil
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. Brazil market estimates and forecasts 2021 to 2033, (USD Million)
9.5.2.5. Target disease prevalence
9.5.3. Mexico
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. Mexico market estimates and forecasts 2021 to 2033, (USD Million)
9.5.3.5. Target disease prevalence
9.5.4. Argentina
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Argentina market estimates and forecasts 2021 to 2033, (USD Million)
9.5.4.5. Target disease prevalence
9.6. MEA
9.6.1. MEA market estimates and forecasts 2021 to 2033, (USD Million)
9.6.2. South Africa
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. South Africa market estimates and forecasts 2021 to 2033, (USD Million)
9.6.2.5. Target disease prevalence
9.6.3. Saudi Arabia
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework
9.6.3.3. Competitive scenario
9.6.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033, (USD Million)
9.6.3.5. Target disease prevalence
9.6.4. UAE
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework
9.6.4.3. Competitive scenario
9.6.4.4. UAE market estimates and forecasts 2021 to 2033, (USD Million)
9.6.4.5. Target disease prevalence
9.6.5. Kuwait
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework
9.6.5.3. Competitive scenario
9.6.5.4. Kuwait market estimates and forecasts 2021 to 2033, (USD Million)
9.6.5.5. Target disease prevalence
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2023
10.4. Company Profiles/Listing
10.4.1. Merck KGaA
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Lonza
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. FUJIFILM Diosynth Biotechnologies
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Thermo Fisher Scientific
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Cobra Biologics
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Catalent Inc.
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Wuxi Biologics
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Takara Bio Inc.
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Waisman Biomanufacturing
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Genezen laboratories
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
10.4.11. Batavia Biosciences
10.4.11.1. Company overview
10.4.11.2. Financial performance
10.4.11.3. Product benchmarking
10.4.11.4. Strategic initiatives
10.4.12. Miltenyi Biotec GmbH
10.4.12.1. Company overview
10.4.12.2. Financial performance
10.4.12.3. Product benchmarking
10.4.12.4. Strategic initiatives
10.4.13. SIRION Biotech GmbH
10.4.13.1. Company overview
10.4.13.2. Financial performance
10.4.13.3. Product benchmarking
10.4.13.4. Strategic initiatives
10.4.14. Virovek Incorporation
10.4.14.1. Company overview
10.4.14.2. Financial performance
10.4.14.3. Product benchmarking
10.4.14.4. Strategic initiatives
10.4.15. BioNTech IMFS GmbH
10.4.15.1. Company overview
10.4.15.2. Financial performance
10.4.15.3. Product benchmarking
10.4.15.4. Strategic initiatives
10.4.16. Audentes Therapeutics
10.4.16.1. Company overview
10.4.16.2. Financial performance
10.4.16.3. Product benchmarking
10.4.16.4. Strategic initiatives
10.4.17. BioMarin Pharmaceutical
10.4.17.1. Company overview
10.4.17.2. Financial performance
10.4.17.3. Product benchmarking
10.4.17.4. Strategic initiatives
10.4.18. RegenxBio, Inc.
10.4.18.1. Company overview
10.4.18.2. Financial performance
10.4.18.3. Product benchmarking
10.4.18.4. Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers